Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$25.99K$25.99Kderived+71.3% vs Q4 2020 Net Income$2.13M$2.13MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$38,997N/M Operating Incomederived-$496,220N/M Operating Cash Flowderived-$233,680N/M Free Cash Flowderived-$237,955— Margins · derivedGross margin-150.1%−85.8 pt vs Q4 2020
Operating margin-1909.5%+372.9 pt vs Q4 2020
Net margin8177.7%+21583.3 pt vs Q4 2020
ended Dec 31, 2021 · filed Apr 15, 2022 · 105 d after period end